Identification of frequent BRAF copy number gain and alterations of RAF genes in chinese prostate cancer

Genes Chromosomes and Cancer

Volumn 51, Issue 11, 2012, Pages 1014-1023

  Ren, Guoping ^a   Liu, Xiaoyan ^a   Mao, Xueying ^b   Zhang, Yanling ^a   Stankiewicz, Elzbieta ^b   Hylands, Lucy ^c   Song, Rongrong ^a   Berney, Daniel M ^b   Clark, Jeremy ^c,d   Cooper, Colin ^c,d   Lu, Yong Jie ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; BRAF GENE; CHINESE; CODON; CORRELATION ANALYSIS; GENE DOSAGE; GENE REARRANGEMENT; GENETIC GAIN; GENOME; HUMAN; HUMAN TISSUE; MALE; ONCOGENE; ONCOGENE K RAS; PRIORITY JOURNAL; PROSTATE CANCER; RAFI GENE;

AGED; BASE SEQUENCE; CHINA; DNA MUTATIONAL ANALYSIS; GENE DOSAGE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF;

EID: 84865996835     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21984     Document Type: Article

References (50)

1. Agell L, Hernandez S, Salido M, de Muga S, Juanpere N, Arumi-Uria M, Menendez S, Lorenzo M, Lorente JA, Serrano S, Lloreta J. 2011. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod Pathol 24: 443-452.
2. Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. 1992. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 52: 5991-5996.
3. Astrom L, Weimarck A, Aldenborg F, Delle U, Hanson C, Verbiene I, Danielsson A, Hammarsten J, Kopf I. 1998. S-phase fraction related to prognosis in localised prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1. Int J Cancer 79: 553-559.
4. Bangma CH, Roemeling S, Schroder FH. 2007. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25: 3-9.
5. Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, Hartmann A, Stoehr R. 2006. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Eur Urol 50: 1102-1109.
6. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Basecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA. 2011. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health. Oncotarget 2: 135-164.
7. Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH. 2006. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer 119: 1858-1862.
8. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, Jacob K, Benner A, Witt H, Remke M, Bender S, Falkenstein F, Van Anh TN, Olbrich H, von Deimling A, Pekrun A, Kulozik AE, Gnekow A, Scheurlen W, Witt O, Omran H, Jabado N, Collins VP, Brummer T, Marschalek R, Lichter P, Korshunov A, Pfister SM. 2011. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol 121: 763-774.
9. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino P. 2006. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95: 1186-1194.
10. Das K, Lau W, Sivaswaren C, Ph T, Fook-Chong S, Sl T, Cheng C. 2005. Chromosomal changes in prostate cancer: a fluorescence in situ hybridization study. Clin Genet 68: 40-47.
11. Edwards J, Krishna NS, Witton CJ, Bartlett JM. 2003. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9: 5271-5281.
12. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. 2006. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 66: 248-256.
13. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. 2003. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 95: 878-889.
14. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. 2006. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci USA 103: 14477-14482.
15. Gumerlock PH, Poonamallee UR, Meyers FJ, deVere White RW. 1991. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 51: 1632-1637.
16. Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U. 2011. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17: 4790-4798.
17. Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, True LD, Roudier MP, Morrissey CM, Higano CS, Nelson PS, Vessella RL, Trask BJ. 2009. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res 69: 7793-7802.
18. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
19. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP. 2008. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68: 8673-8677.
20. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. 2009. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28: 2119-2123.
21. Keller ET, Fu Z, Brennan M. 2005. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 94: 273-278.
22. Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM. 1992. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 69: 2293-2299.
23. Konishi N, Hiasa Y, Tsuzuki T, Tao M, Enomoto T, Miller GJ. 1997. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 30: 53-57.
24. Lee K, Chae JY, Kwak C, Ku JH, Moon KC. 2010. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology 76: e1267-e1213.
25. Liu T, Willmore-Payne C, Layfield LJ, Holden JA. 2009. Lack of BRAF activating mutations in prostate adenocarcinoma: a study of 93 cases. Appl Immunohistochem Mol Morphol 17: 121-125.
26. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M. 2010. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 71: 489-497.
27. Majumder PK, Sellers WR. 2005. Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474.
28. Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, Stankiewicz E, Xue L, Beltran L, Gupta M, Oliver RT, Lemoine NR, Berney DM, Young BD, Lu YJ. 2010. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 70: 5207-5212.
29. Maurer G, Tarkowski B, Baccarini M. 2011. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 30: 3477-3488.
30. Mitelman F, Johansson B, Mertens F. 2007. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7: 233-245.
31. Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E. 2010. ETS family-associated gene fusions in Japanese prostate cancer: Analysis of 194 radical prostatectomy samples. Mod Pathol 23: 1492-1498.
32. Moul JW, Friedrichs PA, Lance RS, Theune SM, Chang EH. 1992. Infrequent RAS oncogene mutations in human prostate cancer. Prostate 20: 327-338.
33. Moyret-Lalle C, Marcais C, Jacquemier J, Moles JP, Daver A, Soret JY, Jeanteur P, Ozturk M, Theillet C. 1995. ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 64: 124-129.
34. Mukherjee R, Bartlett JM, Krishna NS, Underwood MA, Edwards J. 2005. Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate 64: 101-107.
35. Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C, Edwards J. 2011. Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer 104: 1920-1928.
36. Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid UN, Ahmad I. 2005. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 26: 1087-1091.
37. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM. 2010. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16: 793-798.
38. Roobol MJ, Haese A, Bjartell A. 2011. Tumour markers in prostate cancer III: Biomarkers in urine. Acta Oncol 50 (Suppl 1): 85-89.
39. Roskoski R, Jr. 2010. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 399: 313-317.
40. Shen Y, Lu Y, Yin X, Zhu G, Zhu J. 2010. KRAS and BRAF mutations in prostate carcinomas of Chinese patients. Cancer Genet Cytogenet 198: 35-39.
41. Shiraishi T, Muneyuki T, Fukutome K, Ito H, Kotake T, Watanabe M, Yatani R. 1998. Mutations of ras genes are relatively frequent in Japanese prostate cancers: Pointing to genetic differences between populations. Anticancer Res 18: 2789-2792.
42. Sioud M, Leirdal M. 2007. Druggable signaling proteins. Methods Mol Biol 361: 1-24.
43. Skacel M, Ormsby AH, Pettay JD, Tsiftsakis EK, Liou LS, Klein EA, Levin HS, Zippe CD, Tubbs RR. 2001. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: A differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Hum Pathol 32: 1392-1397.
44. Summersgill B, Clark J, Shipley J. 2008. Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat Protoc 3: 220-234.
45. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. 2010. Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
46. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
47. Watanabe M, Shiraishi T, Yatani R, Nomura AM, Stemmermann GN. 1994. International comparison on ras gene mutations in latent prostate carcinoma. Int J Cancer 58: 174-178.
48. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.
49. Woods Ignatoski KM, Grewal NK, Markwart SM, Vellaichamy A, Chinnaiyan AM, Yeung K, Ray ME, Keller ET. 2008. Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. Int J Radiat Oncol Biol Phys 72: 153-160.
50. Zhang BH, Guan KL. 2000. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19: 5429-5439.